MaxCyte, Inc.
NASDAQTotal Valuation
MaxCyte, Inc. carries a market capitalization of 122.12M, placing it among publicly traded companies globally. Its enterprise value stands at -14.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 122.12M |
| Enterprise Value | -14.44M |
Share Statistics
MaxCyte, Inc. currently has 107.12M shares outstanding.
| Shares Outstanding | 107.12M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2.32, and the price-to-book ratio stands at -0.28.
| PE Ratio | N/A |
| PS Ratio | 2.32 |
| PB Ratio | -0.28 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | -2.79 |
| P/OCF Ratio | -2.66 |
Enterprise Valuation
| EV / Sales | 8.25 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
MaxCyte, Inc. maintains a current ratio of 12.04, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.04 |
| Quick Ratio | 10.88 |
| Debt / Equity | 10.42 |
| Debt / EBITDA | -0.53 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -18.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.79 |
Stock Price Statistics
MaxCyte, Inc.'s stock has declined approximately -49.10714% over the past 52 weeks. The 50-day moving average sits at 1.17, while the 200-day moving average is 1.19.
| Beta (5Y) | N/A |
| 52-Week Price Change | -49.10714% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.19 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, MaxCyte, Inc. generated 32.29M in revenue and converted that into -39.12M in net income, yielding earnings per share of -0.37. EBITDA reached -33.27M, while operating income came in at -39.17M.
| Revenue | 32.29M |
| Gross Profit | 25.99M |
| Operating Income | -39.17M |
| Pretax Income | -39.12M |
| Net Income | -39.12M |
| EBITDA | -33.27M |
| EBIT | -39.17M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
MaxCyte, Inc. holds 106.85M in cash and equivalents against 17.49M in total debt, resulting in a net debt position of -14.56M. Total book value stands at -265.16M, with working capital of 112.73M providing operational flexibility.
| Cash & Cash Equivalents | 106.85M |
| Total Debt | 17.49M |
| Net Debt | -14.56M |
| Equity (Book Value) | -265.16M |
| Book Value Per Share | -2.49 |
| Working Capital | 112.73M |
Cash Flow
MaxCyte, Inc. produced -28.17M in operating cash flow over the past twelve months. After subtracting -1.34M in capital expenditures, free cash flow totaled -29.50M - equivalent to -0.28 per share.
| Operating Cash Flow | -28.17M |
| Capital Expenditures | -1.34M |
| Free Cash Flow | -29.50M |
| FCF Per Share | -0.28 |
Margins
MaxCyte, Inc. operates with a gross margin of 80.51, reflecting its pricing power and cost economics. The operating margin of -121.33 and net profit margin of -121.16 provide insight into operational efficiency.
| Gross Margin | 80.51 |
| Operating Margin | -121.33 |
| Pretax Margin | -121.16 |
| Profit Margin | -121.16 |
| EBITDA Margin | -103.06 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.37 |
| FCF Yield | -35.81 |
Scores
MaxCyte, Inc. posts an Altman Z-Score of -0.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.04 |